MRKR
Marker TherapeuticsยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
MRKR Profile
Marker Therapeutics, Inc.
A clinical-stage immuno-oncology company that develops next-generation T cell-based immunotherapies for hematological malignancies and solid tumor indications
Biological Technology
--
11/08/2016
NASDAQ Stock Exchange
5
12-31
Common stock
9350 Kirby Drive, Suite 300, Houston, Texas 77054
--
Marker Therapeutics, Inc., is a clinical-stage immuno-oncology company specializing in the development of next-generation T-cell immunotherapies for the treatment of hematological malignancies and solid tumor indications. Marker's cell therapy technology is based on the selective expansion of unengineered tumor-specific T cells, which recognize tumor-associated antigens (i.e., tumor targets) and kill tumor cells expressing these targets. Once transfused into the patient, this group of T cells attacks multiple tumor targets and acts to activate the patient's immune system to generate broad-spectrum anti-tumor activity. Since Marker does not genetically engineer its T cells, its products are (i) less expensive, easier to manufacture, (ii) significantly less toxic, and (iii) associated with meaningful clinical benefits compared to current CAR-T and TCR-based engineering methods. Therefore, Marker believes that its T-cell therapy portfolio has a compelling therapeutic product profile compared to current genetically modified CAR-T and TCR-based therapies.
